AMN Healthcare Services enters its Q1 2026 earnings call on May 7 with a stock that has rebounded sharply from its April lows — yet options traders are quietly loading up on downside protection, creating a notable tension between price momentum and market caution.
The clearest signal of unease sits in options positioning. The put/call ratio has climbed to 0.34, more than two standard deviations above its 20-day average of 0.28. That z-score of 2.09 is the highest defensive reading since late March, when the PCR briefly spiked above 0.40 before collapsing back toward historic lows. Investors who held calls through that period were rewarded — the stock is up 11% over the past month to $20.93. But with the earnings call now days away, the options market is re-hedging rather than extending that bet.
The short positioning tells a contrasting story. Short interest has been in a clear downward trend since late March, easing from a recent peak of roughly 7.4% of the free float in late March to around 6.75% now. Over the past week alone, estimated SI fell just under 2%. Borrow conditions remain relaxed — cost to borrow is a negligible 0.49%, and availability is ample, well into the thousands-of-percent range relative to shares short. There is no squeeze pressure and no meaningful rush by new short-sellers to press the trade ahead of results. If anything, prior shorts have been closing out positions into the stock's recovery.
On the Street, the picture is mixed but not hostile. Recent analyst moves — all from around February's Q4 print — were largely target raises with unchanged ratings. Citizens and BMO Capital both lifted their targets, while UBS moved to $19.50 (since overtaken by the stock's bounce to $20.93). The consensus leans cautiously toward Hold, though a couple of names carry Outperform or Buy ratings. The mean target of ~$22 implies modest upside from current levels. Valuation has re-rated noticeably over the past month: the P/E has expanded by roughly 1.7 turns to nearly 12x, and price-to-book is up 0.15x over the same period as the recovery took hold. EV/EBITDA at 6.8x is grinding higher but not stretched. Factor scores send a split signal — 90-day EPS momentum ranks in the 98th percentile of the universe, reflecting the strong earnings surprise history, yet 30-day EPS momentum sits near the bottom at the 14th percentile, suggesting near-term estimate drift has reversed.
That earnings surprise history is worth dwelling on. The Q4 print on February 19 triggered a single-day move of 20% and a five-day move of 13%. The prior quarter showed an almost identical pattern. AMN has consistently printed above both revenue and EBITDA expectations, with an average revenue surprise of +3% and EBITDA surprise of +12% over recent quarters. Bears point to ongoing structural headwinds — nurse and allied segment revenues still declining double-digits year-on-year, a 31% drop in vendor management system revenue, and operating margins under pressure. Bulls counter that gross margins have been improving and that the company has a track record of beating whatever low bar analysts set. The Q4 result was reported on revenue of $748M against the prior year's $735M — a sequential recovery that provided the fuel for February's gap higher.
On the institutional side, BlackRock holds just over 15% and Vanguard around 9%, both essentially passive holders with minimal recent change. Millennium Management added a material position in Q4 2025 — just under 1.8 million shares — which is the most notable active-money move in the holder table. The ORTEX short score of 41 is unremarkable, sitting in roughly the 37th percentile of the universe; this is not a high-conviction short by any aggregate metric. What to watch heading into May 7 is whether the gross margin recovery narrative holds, and whether the vendor management segment finds a floor — those two data points have driven AMN's earnings-day volatility more than headline revenue in recent quarters.
See the live data behind this article on ORTEX.
Open AMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
